Press Releases

June 27 2012

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

June 21 2012

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

May 24 2012

BIO commends the bipartisan Senate approval of FDASIA, which includes a reauthorization of the...

May 9 2012

Global event for biotechnology to be held June 18-21, 2012 in Boston.

March 29 2012

Sara Radcliffe, Executive Vice President of Health at the Biotechnology Industry Organization...

February 1 2012

In the testimony, Richard Pops, Alkermes plc Chairman and CEO,  stressed the...

January 13 2012

BIO strongly supports the PDUFA V recommendations as they will enhance the drug development...

October 24 2011

In a public meeting hosted by FDA, BIO  expressed strong support for the PDUFA V...

September 1 2011

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

September 21 2007

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

September 19 2007

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

January 11 2007

The recommended improvements to the Prescription Drug User Fee Act (PDUFA) announced today by...

May 22 2002

The House of Representatives today voted 425-1 to approve “The Public Health Security...

February 24 2014
The Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO) are pleased to submit these comments in response to the Food and Drug Administration’s (FDA’s) Draft Prescription Drug User Fee Act V (PDUFA V) Information Technology Plan (IT Plan).
September 13 2013
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans.” BIO commends FDA on the release of this Draft Guidance and shares the Agency’s commitment to ensure that safe and effective medicines are available for children.
May 7 2013
BIO thanks the Food and Drug Administration for the opportunity to submit comments on the FDA Draft Plan on “Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision Making.”
October 1 2012
Pharmaceutical Research and Manufacturers of America PhRMA President and CEO John J. Castellani and BIO President and CEO Jim Greenwood released the following joint statement on the implementation of the Prescription Drug User Fee Act (PDUFA V).
June 27 2012
Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on passage of S. 3187, the Food and Drug Administration Safety and Innovation Act (FDASIA), by the U.S. Senate.
June 21 2012
Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on unanimous passage of S. 3187, the Food and Drug Administration Safety and Innovation Act (FDASIA), by the U.S. House of Representatives.
May 24 2012
BIO commends the bipartisan Senate approval of FDASIA, which includes a reauthorization of the Prescription Drug User Fee Act (PDUFA).  
May 9 2012
Global event for biotechnology to be held June 18-21, 2012 in Boston.